Biostate AI Raises $12M Series A to Advance AI-Powered RNA Sequencing
Biostate AI, a pioneering biotech startup, has raised $12 million in a Series A funding round. The investment was led by Accel, with participation from Gaingels, Mana Ventures, InfoEdge Ventures, and returning investors such as Matter Venture Partners, Vision Plus Capital, and Catapult Ventures. Notable angel investors from leading biotech and AI companies also joined the round.
Scaling RNAseq for Precision Medicine
The funding will accelerate the growth of Biostate AI’s AI-powered RNA sequencing (RNAseq) platform. The company is focusing on making precision medicine more affordable and integrated. Key goals include expanding disease datasets, improving predictive models, and forming deeper collaborations in oncology, cardiovascular, and autoimmune research.
Biostate AI aims to overcome the high cost and fragmentation in conventional RNA sequencing. The team is building a scalable system that can generate consistent, high-throughput data for advanced AI training. Their platform focuses on full-transcriptome analysis, enabling better detection of early disease signals and treatment responses.
Also read: BingX Commits $300M to AI as It Shifts Focus Toward Intelligent Web3 Innovation
Technological Innovations Driving Growth
The company’s platform is based on patented sequencing technologies such as BIRT and PERD. These allow for accurate RNAseq from both fresh and archived tissue samples. By dramatically reducing sequencing costs, the platform becomes accessible to a wide range of research institutions and biotech firms.
To further support researchers, Biostate has built tools like Quantaquill, which helps translate raw sequencing data into structured, publication-ready insights. The entire pipeline is designed to streamline workflows, reduce batch effects, and improve the consistency of RNA data across thousands of samples.
Building a Leading RNAseq Dataset
Biostate AI has already processed over 10,000 samples through partnerships with more than 150 organizations. With plans in place to scale to hundreds of thousands of samples annually, the company is building one of the largest AI-ready RNAseq datasets globally.
This growth positions Biostate AI at the forefront of a new generation of AI-native biomedical platforms, combining deep data pipelines with cutting-edge machine learning to push the boundaries of disease detection and treatment.
